In the double-blind randomized clinical phase I trial (NCT04056689) conducted by Denali Therapeutics, DNL151, an LRRK2 inhibitor, showed a fairly clear therapeutic benefit on Parkinson’s disease. Here, LRRK2 is linked to Parkinson disease.